Calidi Biotherapeutics Launches Nova Cell Subsidiary And Announces $1M Subscription Agreement From Dr. Ronald Rigor To Purchase A Combination Of CLDI Stock At A 10% Discount To The Closing Price On July 22, 2024 And Warrants To Purchase 600K Shares Of Stock At A 20% Premium To The Closing Price On July 22, 2024; And $2M To Purchase Common Stock Of Nova Cell
Portfolio Pulse from Benzinga Newsdesk
Calidi Biotherapeutics (NYSE:CLDI) has launched a new subsidiary, Nova Cell, and announced a $2 million investment from Dr. Ronald Rigor. Dr. Rigor also invested an additional $1 million in Calidi, purchasing CLDI stock at a discount and warrants at a premium. He joins Calidi's Scientific and Medical Advisory Board.
July 29, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Calidi Biotherapeutics (NYSE:CLDI) has received a $3 million investment from Dr. Ronald Rigor, including $2 million for its new subsidiary, Nova Cell, and $1 million for CLDI stock and warrants. Dr. Rigor also joins Calidi's Scientific and Medical Advisory Board.
The $3 million investment and the launch of Nova Cell are significant positive developments for Calidi Biotherapeutics. The investment will help advance their stem cell programs and oncology pipeline, likely boosting investor confidence and stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100